Company intelligence / Profile preview

Lutris Pharma

Ownership: Private
Development stage: Phase 2

Overview

Lutris Pharma has completed a Phase 1 clinical trial for LUT014 in metastatic colorectal cancer patients with EGFR inhibitor-induced acneiform lesions, providing first evidence of treatment effectiveness. The company has also successfully completed a Phase 1/2 trial for LUT-RD, demonstrating efficacy and safety of LUT014 gel in breast cancer patients with radiation dermatitis. Currently, LUT014 is in Phase 2 clinical trials at leading US oncological centers.[1][2][5]

Therapeutic areas: Dermatology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

LUT014

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Lutris Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lutris Pharma.

Explore the full profile